(Q43011791)

English

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium

scientific article published in September 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

metastatic melanoma

1 reference

based on heuristic

inferred from title

John D Hainsworth

1

object named as

John D Hainsworth

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Jeffrey R Infante

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

David R Spigel

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

James D Peyton

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Dana S Thompson

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Cassie M Lane

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Bobby L Clark

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Mark S Rubin

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

David F Trent

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Howard A Burris

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

1 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

116

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

4122-4129

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

Targeting the molecular target of rapamycin (mTOR).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

Toward a molecular classification of melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

Deregulated Akt3 activity promotes development of malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

Therapeutic strategies for inhibiting oncogenic BRAF signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

21 January 2018

Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25320

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25320

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43011791&oldid=1976557511"